Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Temafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.62 |
| ▸ | HPGD | P15428 | 8/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temafloxacin SCHEMBL2637551 | 1.00 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL134293 | 1.00 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL20769825 | 0.99 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL134294 | 0.99 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL48095 | 0.99 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| (S)-Temafloxacin SCHEMBL48096 | 0.99 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL29414891 | 0.99 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| (S)-Temafloxacin SCHEMBL9667109 | 0.98 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL9667105 | 0.98 | ALDH1A1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| Temafloxacin SCHEMBL313347 | 0.97 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| CN-113527288-A | Process for preparing quinolone-or naphthyridonecarboxylic acid derivatives | 沈阳药科大学 | 2021-10-22 | — | — | CN | claimed |
| CN-112912386-A | Cell penetrating peptide based on influenza virus M2 protein | 中国医学科学院基础医学研究所 | 2021-06-04 | — | — | CN | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20120093759-A1 | Medical Devices, Wound Dressings, and Methods for Dressing Wounds | VACHON DAVID J (US) | 2012-04-19 | — | — | US | claimed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | ALDH1A1 2937/4885KDM4E 4586/4885HPGD 1115/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | ALDH1A1 2641/4885KDM4E 2014/4885HPGD 3568/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | ALDH1A1 2720/4885KDM4E 4063/4885HPGD 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.